Healthcare
Dr. Reddy's Laboratories Limited(RDY)
Live Price
Offline$13.36
+0.45% today
1Y Change
-13.66%
Window
Jun 20, 2025 โ Jun 17, 2026
- Market Cap
- $1.10T
- Revenue Growth
- +16.6%
- EPS Growth
- +1.6%
- Dividend Yield
- 1.2%
Coverage: 249 bars ยท Jun 20, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Dr. Reddy's Laboratories Limited (RDY) is a Healthcare stock with a market cap of $1.10T and listed on NYSE. The stock last traded around $13.36 and down 13.7% across the available one-year price window (Jun 20, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +16.6%, EPS growth of +1.6%, a dividend yield of 1.2%. What stands out right now is revenue +16.6%, EPS +1.6%, free cash flow -33.2% with operating margin 19.3% and ROIC 11.2%. The dividend is present but secondary, with a yield around 1.2%. Valuation is more restrained than many high-expectation growth names at P/E 19.5 and price/sales 3.2. Stock Foundry combines RDY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+16.6% vs +7.6% peer median
Operating Margin
Near sector median
+19.3% vs +19.4% peer median
P/E
Below sector median
19.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report came in below the EPS bar
2026 was reported on May 12, 2026 with an EPS surprise of -33.3% and a revenue surprise of -11.0%.
The operating story is still moving forward
Revenue is running at +16.6% and EPS at +1.6%, with operating margin around 19.3%.
The next real check-in already has a date
The next earnings event is scheduled for Jul 22, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | -33.3% | +4.3% | +7.9% | +6.7% |
2026 Jan 20, 2026 | +0.0% | +2.6% | +6.0% | +11.4% |
2025 Oct 24, 2025 | -1.4% | -0.8% | -8.8% | -4.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RDY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RDY Max Drawdown
-20.08%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RDY and SPY.
Company Overview
Dr. Reddy's Laboratories Limited
New York Stock Exchange
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
- Leadership
- Erez Israeli
- IPO Date
- Apr 11, 2001
- Employees
- 27.0k
- Street Address
- 8-2-337, Road No. 3
- Mailing
- Hyderabad, 500034
- Region
- Hyderabad, IN
- Reporting Currency
- USD
- Investor Line
- 91 40 4900 2900
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 19.5
- EV/EBITDA
- 13.1
- Price/Sales
- 3.2
- Price/Book
- 3.0
Growth
- Revenue
- +16.6%
- EPS
- +1.6%
- Free Cash Flow
- -33.2%
Profitability
- Gross Margin
- 55.2%
- Operating Margin
- 19.3%
- Net Margin
- 16.4%
- ROE
- 16.0%
- ROIC
- 11.2%
Balance Sheet
- Debt/Equity
- 0.21
- Current Ratio
- 1.88
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.